Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015371 | 0.90 | CHRNA7 (0.48) | CHRNA7KCNH2DRD4DRD2DRD3 | |
| SCHEMBL781435 | 0.87 | CHRNA7 (0.45) | CHRNA7KCNH2DRD4DRD2DRD3 | |
| SCHEMBL777680 | 0.86 | CHRNA7 (0.68) | CHRNA7KCNH2 | |
| Hydrochloric Acid SCHEMBL777960 | 0.85 | KCNH2 (0.68) | CHRNA7KCNH2 | |
| SCHEMBL799590 | 0.80 | GPR119 (0.39) | CHRNA7KCNH2 | |
| SCHEMBL782693 | 0.80 | GPR119 (0.39) | CHRNA7 | |
| SCHEMBL781330 | 0.78 | CHRNA7 (0.55) | CHRNA7KCNH2 | |
| SCHEMBL14346582 | 0.78 | CHRNA7 (0.55) | CHRNA7KCNH2 | |
| Hydrochloric Acid SCHEMBL779757 | 0.77 | KCNH2 (0.56) | CHRNA7KCNH2 | |
| SCHEMBL779891 | 0.74 | CHRNA7 (0.66) | CHRNA7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885KCNH2 465/4885DRD4 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.